Compare CHCO & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CHCO | NNNN |
|---|---|---|
| Founded | 1957 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | N/A | 2025 |
| Metric | CHCO | NNNN |
|---|---|---|
| Price | $119.53 | $30.71 |
| Analyst Decision | Hold | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $128.33 | N/A |
| AVG Volume (30 Days) | ★ 103.9K | 39.3K |
| Earning Date | 01-22-2026 | 04-28-2026 |
| Dividend Yield | ★ 2.92% | N/A |
| EPS Growth | ★ 11.27 | N/A |
| EPS | ★ 8.68 | 0.06 |
| Revenue | ★ $307,880,000.00 | $6,920,153.00 |
| Revenue This Year | $10.45 | N/A |
| Revenue Next Year | $3.18 | N/A |
| P/E Ratio | ★ $13.74 | $512.73 |
| Revenue Growth | ★ 6.33 | N/A |
| 52 Week Low | $102.22 | $5.18 |
| 52 Week High | $133.59 | $55.65 |
| Indicator | CHCO | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 36.12 | 45.19 |
| Support Level | $118.43 | $31.18 |
| Resistance Level | $124.43 | $38.00 |
| Average True Range (ATR) | 2.50 | 3.52 |
| MACD | -0.73 | -0.59 |
| Stochastic Oscillator | 9.20 | 16.58 |
City Holding Co is a financial holding company. The company conducts its principal activities through its wholly-owned subsidiary, City National Bank of West Virginia (City National). Through the bank, it provides banking, trust and investment management, and other financial solutions through its network of banking offices located in the states of West Virginia, Virginia, southeastern Ohio, and Kentucky. It offers various products and services such as overdraft facilities, savings accounts, credit cards and debit cards, loans for various purposes, investment advisory, securities brokerage, insurance products, and others. The company's business activities are currently limited to one reportable business segment, which is community banking.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.